Description
NEXIUM-MUPS® is indicated for: Relief of upper gastrointestinal symptoms, healing and maintenance of lesions in patients requiring reduction of acid secretion.
NEXIUM-MUPS® 40 mg is used as initial treatment in:
– Symptom control and healing of gastric acid-related injuries including acute and chronic gastritis.
– Gastroesophageal Reflux Disease (GERD): symptomatic treatment of GERD; scarring of reflux esophagitis; prevent relapses in the long-term treatment of healed esophagitis.
– Healing of peptic ulcers not associated with H. pylori.
– Healing of gastric ulcers associated with therapy with non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective NSAIDs.
– Prevention in patients at high risk of gastric and duodenal ulcers associated with therapy with non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective NSAIDs.
– Pathological states of hypersecretion considering Zollinger-Ellison syndrome and idiopathic hypersecretion.
– Prevention of gastric and duodenal ulcers associated with therapy with low doses (75-325 mg) of acetylsalicylic acid (Aspirin) in patients at risk.
– After treatment with NEXIUM IV®: maintenance of hemostasis and prevention of rebleeding of gastric or duodenal ulcers.
NEXIUM-MUPS® 20 mg is used in the initial treatment for:
– Symptomatic GERD without esophagitis.
– Helicobacter pylori eradication in combination with appropriate antibiotics: to heal H. pylori-associated duodenal ulcers, and prevent relapses in patients with H. pylori-associated peptic ulcers.
– Symptomatic treatment of heartburn, dysphagia, regurgitation (heartburn), epigastric pain, gastritis.
– Non-ulcer dyspepsia.
It is indicated for long-term treatment for:
– Avoid recurrences in healed esophagitis.
– Control of GERD symptoms.
– Healing of gastric ulcers associated with therapy with non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective NSAIDs.
– Prevention in patients at high risk of gastric and duodenal ulcers associated with therapy with non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective NSAIDs.
– Prevention of gastric and duodenal ulcers associated with therapy with low doses (75-325 mg) of acetylsalicylic acid (aspirin) in patients at risk.
– After treatment with NEXIUM IV®: maintenance of hemostasis and prevention of rebleeding of gastric or duodenal ulcers.
Reviews
There are no reviews yet.